CVRx

CVRX

Market cap $143M

CVRx, Inc. (CVRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited fourth quarter and full year 2025 revenue results as well as provided a 2026 business outlook.

MINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, confirmed today that Category I Current Procedural Terminology (CPT) codes for baroreflex activation therapy using its Barostim device replaced the Category III codes as of Jan. 1, 2026. In the U.S. healthcare system, Category I CPT codes signify established procedures, supporting adoption, coverage, and reimbursement nationwide.

MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The Company's presentation will begin at 3:45 p.m. (PT).  A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

MINNEAPOLIS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, Dec. 3, 2025. The fireside chat is scheduled at 2:00 p.m. (ET) the same day via webcast.

CVRx, Inc. ( CVRX ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Kevin Hykes - President, CEO & Director Jared Oasheim - Chief Financial Officer Conference Call Participants Mike Vallie - Westwicke Partners, LLC John Young - Canaccord Genuity Corp., Research Division Samantha Munoz - Piper Sandler & Co., Research Division Rohin Patel - JPMorgan Chase & Co, Research Division Max Smock Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division Presentation Operator Greetings, and welcome to the CVRx Third Quarter 2025 Earnings Conference Call. As a reminder, this conference is being recorded.

CVRx (CVRX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.57 per share a year ago.

MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2025 financial and operating results after market close on Wednesday, Nov. 5, 2025. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.

CVRx (CVRX) Q2 Revenue Jumps 15%

Call Start: 16:30 January 1, 0000 5:09 PM ET CVRx, Inc. (NASDAQ:CVRX ) Q2 2025 Earnings Conference Call August 04, 2025, 04:30 PM ET Company Participants Jared Oasheim - Chief Financial Officer Kevin Hykes - President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C., Research Division Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division John Edward Young - Canaccord Genuity Corp., Research Division Rohin Kirit Patel - JPMorgan Chase & Co, Research Division Ross Everett Osborn - Cantor Fitzgerald & Co., Research Division Samantha Munoz - Piper Sandler & Co., Research Division Michael Vallie - Unidentified Company Operator Good afternoon, ladies and gentlemen.